IQVIA Holdings In…
USUSDIQVIA Holdings Inc (LSE:0JDM) — Biotechnology: Commercial Physical & Biological Resarch. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- iqvia.com
- Investorite Suhted
- ir.iqvia.com/
- Sektor
- Health Care · Biotechnology: Commercial Physical & Biological Resarch
- Peakontor
- Durham, United States
- Tegevjuht
- Ari Bousbib
- Töötajad
- 94 000
- Asutatud
- 2016
- Börsil Alates
- 29.01.2018 (LSE:0JDM)
- Ringluses Olevad Aktsiad
- 164.6 mln seisuga 2026-07-21
- Vabalt Kaubeldavad Aktsiad
- 156.25 mln
- Turukapitalisatsioon
- 44.25 mld USD
- Siseringi Isikud
- 1.09%
- Institutsionaalsed Investorid
- 103.42%
- Tegevusala (SIC)
- Services-Commercial Physical & Biological Research
- ISIN
- US46266C1053
- LEI
- 549300W3R20NM4KQPH86
- P/E
- 47.1
- Väljamaksesuhe
- 41.0%
- FCF
- 2.12 mld USD
- Väljamakse / FCF
- 27%
- Võlg
- 15.8 mld USD6.6 a FCF
- Dividendistaaž
- —
- Kasum, FCF ja dividendid makstud — 12 kuu jooksul kuni 31.03.2026 (ettevõtte viimane raport).
- NAV
Kirjeldus
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Dividendid
Dividendimakseid ei leitud (kontrollitud 19.10.2026). Ettevõte ilmselt dividende ei maksa.
Selle Nädala Uudised
Pressiteated ettevõtte investorite veebisaidilt, uuendatakse iga päev. Lingid viivad ettevõtte veebilehele. Pealkirjad on originaalkeeles, nagu ettevõtte veebilehel.
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| Blackrock Inc. | 8.84% | 14.55 mln | 2026-06-30 |
| Harris Associates L.P. | 7.4% | 12.18 mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.63% | 10.91 mln | 2026-06-30 |
| State Street Corporation | 4.56% | 7.51 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.56% | 7.5 mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.73% | 6.14 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.22% | 5.3 mln | 2026-06-30 |
| Artisan Partners Limited… | 2.88% | 4.74 mln | 2026-06-30 |
| Boston Partners | 2.71% | 4.47 mln | 2026-06-30 |
| Geode Capital Management… | 2.71% | 4.45 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.63% | 4.32 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.2% | 3.62 mln | 2026-06-30 |
| Invesco Ltd. | 1.99% | 3.28 mln | 2026-06-30 |
| HARRIS ASSOCIATES INVEST… | 1.58% | 2.61 mln | 2026-06-30 |
| HARRIS ASSOCIATES INVEST… | 1.56% | 2.57 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 2.22 mln | 2026-08-31 |
| Fidelity Concord Street… | 1.31% | 2.16 mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.24% | 2.04 mln | 2026-08-31 |
| VANGUARD WINDSOR FUNDS-V… | 1.07% | 1.76 mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.96% | 1.59 mln | 2026-06-30 |
| BOUSBIB ARI B (Chief Exe… | ≈0.84% | 1.38 mln | 2026-07-29 |
| BRUEHLMAN RONALD E (Chie… | ≈0.03% | 55 996 | 2026-02-06 |
| HAAS BERND (Officer) | ≈0.01% | 24 414 | 2026-02-06 |
| GRENFELL ALISTAIR (Offic… | ≈0.01% | 24 124 | 2026-02-06 |
| SHERBET ERIC M (General… | ≈0.01% | 20 999 | 2026-07-29 |
| LEONARD JOHN M (Director… | ≈0.01% | 16 946 | 2026-04-23 |
| GOGGINS COLLEEN A (Direc… | ≈0.01% | 14 453 | 2026-04-23 |
| STAUB WALTER. RICHARD II… | ≈0.01% | 13 312 | 2026-08-03 |
| FEDOCK MICHAEL J. (Offic… | ≈0.01% | 9 595 | 2026-02-06 |
| DANHAKL JOHN G (Director… | — | — | 2026-04-23 |
Logi Sisse Google